兆科眼科-B(06622.HK) 董事会主席、执行董事兼首席执行官李小羿预期,集团旗下多个产品申请将陆续于下半年获批。当中,李小羿表示,国家药监局已于去年5月受理环孢素眼用凝胶的新药申请,并已在去年6月获得FDA批准新药试验申请。硫酸阿托品滴眼液(NVK002)现正接受监管审查以取得上市批准。而用于治疗湿性老年黄斑部病变的贝伐单抗玻璃体腔内注射液(TAB014),已于中国提交生物制剂许可申请,预计...
Source Link兆科眼科-B(06622.HK) 董事会主席、执行董事兼首席执行官李小羿预期,集团旗下多个产品申请将陆续于下半年获批。当中,李小羿表示,国家药监局已于去年5月受理环孢素眼用凝胶的新药申请,并已在去年6月获得FDA批准新药试验申请。硫酸阿托品滴眼液(NVK002)现正接受监管审查以取得上市批准。而用于治疗湿性老年黄斑部病变的贝伐单抗玻璃体腔内注射液(TAB014),已于中国提交生物制剂许可申请,预计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.